Alpha Healthcare Acquisition Corp. III merges with Carmell Therapeutics at $150M implied equity value

Longevity Health Holdings, Inc.

Carmell shareholders receive 15M ALPA Class A shares; implied Carmell equity value $150M.
Combined company expected market cap ~$328M; Carmell shareholders own ~46% post-close.
Transaction expected to close H1 2023; combined co. to list on Nasdaq as 'CTCX'.
Carmell is a Phase 2 biotech with allogeneic plasma-based biomaterials; FDA Fast Track for tibia fracture.
Rajiv Shukla to become Chairman, Randy Hubbell to serve as CEO of combined company.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Longevity Health Holdings, Inc. entered into Business Combination Agreement with Carmell Therapeutics Corporation valued at an implied Carmell equity value of $150,000,000 (effective 2023-01-04).

Action: entry
Agreement: merger
Counterparty: Carmell Therapeutics Corporation
Value: an implied Carmell equity value of $150,000,000
Effective: 2023-01-04

Exact text from the filing

On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (the " Company "), entered into a business combination agreement (the " Business Combination Agreement ") by and among the Company, Candy Merger Sub, Inc., a Delaware corporation (" Merger Sub "), and Carmell Therapeutics Corporation, a Delaware corporation (" Carmell ").

View on SEC.gov

Browse all material agreements →

Longevity Health Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-001591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.